G&A

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Retrieved on: 
Thursday, February 15, 2024

WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.   

Key Points: 
  • “Our partnership with AbCellera represents a strategic step to expand our pipeline, based on our core competencies in medicinal chemistry, cancer biology and clinical development.
  • A second cohort of patients with AML is expected to initiate in the first half of 2024.
  • Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.
  • The decrease in general and administrative expenses was primarily due to our continued management of general and administrative expenses.

Zoomcar Reports Fiscal Third Quarter 2023 Results

Retrieved on: 
Wednesday, February 14, 2024

BANGALORE, India, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zoomcar Holdings, Inc. (Nasdaq: ZCAR) (“Zoomcar,” the “Company,” “we,” or “our”), the leading marketplace for car sharing in emerging markets, today reported select financial results for the third fiscal quarter ended December 31, 2023.

Key Points: 
  • BANGALORE, India, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zoomcar Holdings, Inc. (Nasdaq: ZCAR) (“Zoomcar,” the “Company,” “we,” or “our”), the leading marketplace for car sharing in emerging markets, today reported select financial results for the third fiscal quarter ended December 31, 2023.
  • In FQ3 2023, Zoomcar Hosts earned approximately $4 million.
  • Zoomcar achieved a record average transaction size of over $75 per booking during the quarter.
  • Results compare 2023 fiscal third quarter end (December 31, 2023) to 2022 fiscal third quarter end (December 31, 2022) unless otherwise indicated.

FCPT Announces Fourth Quarter 2023 Financial and Operating Results

Retrieved on: 
Wednesday, February 14, 2024

Four Corners Property Trust, Inc. (“FCPT” or the “Company”, NYSE: FCPT) today announced financial results for the three months and twelve months ended December 31, 2023.

Key Points: 
  • Four Corners Property Trust, Inc. (“FCPT” or the “Company”, NYSE: FCPT) today announced financial results for the three months and twelve months ended December 31, 2023.
  • NAREIT-defined FFO per diluted share for the fourth quarter was $0.41, representing a $0.01 increase compared to the same quarter in 2022.
  • FCPT declared a dividend of $0.345 per common share for the fourth quarter of 2023.
  • During the fourth quarter, FCPT sold one property for sales price of $3.8 million representing $0.3 million of gain.

NETSTREIT Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on: 
Wednesday, February 14, 2024

Reflects 5,983,711 of unsettled forward equity shares under the ATM program at the December 31, 2023 available net settlement price of $16.48.

Key Points: 
  • Reflects 5,983,711 of unsettled forward equity shares under the ATM program at the December 31, 2023 available net settlement price of $16.48.
  • On February 13, 2024, the Company’s Board of Directors declared a quarterly cash dividend of $0.205 per share for the first quarter of 2024.
  • The Company is reaffirming its initial full year 2024 AFFO per share guidance in the range of $1.24 to $1.28.
  • During the conference call the Company’s officers will review fourth quarter and full year 2023 performance, discuss recent events, and conduct a question and answer period.

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 14, 2024

CRANFORD, N.J., Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter 2024 ended December 31, 2023.

Key Points: 
  • "We had a strong first quarter of fiscal 2024 during which we achieved multiple mission critical goals.
  • FIRST QUARTER 2024 Financial Results:
    As of December 31, 2023, the Company had $20.3 million in cash and cash equivalents.
  • R&D expenses were $2.6 million for the first quarter ended December 31, 2023, compared to $3.4 million for the first quarter ended December 31, 2022.
  • G&A expenses were $3.7 million for the first quarter ended December 31, 2023, compared to $2.6 million for the first quarter ended December 31, 2022.

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 14, 2024

Financial results for the full year ended December 31, 2023

Key Points: 
  • Financial results for the full year ended December 31, 2023
    R&D expenses, net for the year ended December 31, 2023, were $16.1 million, compared to $28 million in 2022.
  • G&A expenses for the year ended December 31, 2023, were $5.5 million, compared to $8.0 million for 2022.
  • Marketing and business development expenses for the year ended December 31, 2023, were $1.2 million, compared to $2.9 million for 2022.
  • PolyPid expects that its pro forma cash balance will be sufficient to fund operations into late third quarter 2024.

NanoXplore Reports Results for its Q2-2024

Retrieved on: 
Tuesday, February 13, 2024

Other income increased from $393,111 in the last year period to $732,913 in the current period.

Key Points: 
  • Other income increased from $393,111 in the last year period to $732,913 in the current period.
  • Results of operations may include certain unusual and other items which have been separately disclosed, where appropriate, in order to provide a clear assessment of the underlying Corporation results.
  • NanoXplore will hold a webcast tomorrow, February 14, 2024, at 8:30 am EDT to review its Q2-2024.
  • Soroush Nazarpour, CEO and President of NanoXplore, and Pedro Azevedo, Chief Financial Officer, will host the event.

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 13, 2024

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.
  • As of February 12, 2024, the Company had 27,029,731 shares of common stock issued and 3,577,240 pre-funded warrants outstanding.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.
  • In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Tuesday, February 13, 2024.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
Tuesday, February 13, 2024

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.